Table 1.
Demographics and characteristics of patients prior to mobocertinib administration.
| Characteristics | N = 16 |
|---|---|
| Age | |
| Median (range), years | 65 (38-83) |
| Gender, n (%) | |
| Male | 4 (25) |
| Female | 12 (75) |
| Smoking history, n (%) | |
| Former | 6 (37.5) |
| Never | 9 (56.3) |
| Current | 1 (6.2) |
| Histology, n (%) | |
| Adenocarcinoma | 16 (100) |
| Stage of disease at diagnosis, n (%) | |
| IV | 16 (100) |
| PD-L1 status, n (%) | |
| >50% | 1 (6.3) |
| 1-49% | 5 (31.3) |
| <1% | 8 (50) |
| N/A | 2 (12.4) |
| ECOG, n (%) | |
| 0 | 8 (50) |
| 1 | 5 (31.3) |
| 2 | 2 (12.4) |
| N/A | 1 (6.3) |
| Brain metastasis before Mobocertinib, n (%) | |
| No | 8 (50) |
| Yes | 8 (50) |
| Mobocertinib line of treatment, n (%) | |
| 1st | 5 (31.3) |
| 2nd | 8 (50) |
| 3rd | 3 (18.7) |
| EGFRex20ins mutation, n (%) | |
| A763_Y764insFQEA | 1 (6.3) |
| A767_V769dup | 1 (6.3) |
| V769_D770insASV | 2 (12.5) |
| D770_N771insG | 1 (6.3) |
| D770_N771insSVD | 1 (6.3) |
| D770_N771insGL | 1 (6.3) |
| D770_P772dup | 1 (6.3) |
| D770delinsDGP | 1 (6.3) |
| D770delinsDNPH | 1 (6.3) |
| N771_H773dup | 2 (12.5) |
| N771>GY | 1 (6.3) |
| H773_V774insAH | 1 (6.3) |
| H773_V774delinsLM | 1 (6.3) |
| N/A | 1 (6.3) |
ECOG, Eastern Cooperative Oncology Group; N/A, not available/not applicable; PD-L1, Programmed death-ligand 1; EGFRex20ins, EGFR exon 20 insertion; RT, radiotherapy.